AlenCiken

FDA Approval of IDE Supplement for COVID-19 Patients

NASDAQ:AEMD   AETHLON MEDICAL INC
Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients

(FDA) has approved a supplement to the Company's existing Investigational Device Exemption ( IDE ) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit ( ICU ) and will have acute lung injury and/or severe or life threatening disease among other criteria.

"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19. We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."

The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies. The Hemopurifier also holds a Breakthrough Device designation

https://finance.yahoo.com/news/aethlon-a...

https://www.bloomberg.com/news/articles/...

Comments

hoping it shoots to $5-6
Reply
AlenCiken smoovetheGOAT
Reply
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out